A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB14 in Patients With Advanced Malignant Solid Tumours
Latest Information Update: 18 Mar 2024
At a glance
- Drugs SCT B14 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sinocelltech
- 18 Mar 2024 New trial record